Mangrove Partners’s Biogen BIIB Stock Holding History

Mangrove Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-103,200	Closed	-$28.9M	–	327
2021 Q1	$28.9M	Buy	+103,200	New	+$27.8M	2.91%	2

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mangrove Partners's BIIB Position: Q4 2024 in Review

Mangrove Partners sold out of Biogen (BIIB) in Q4 2024, closing a stake of 4,582 shares — an estimated $888K sold.

Mangrove Partners first reported a position in BIIB in Q3 2021 and held it in 2 quarters. The position peaked at $13M in Q3 2021. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Mangrove Partners reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Mangrove Partners sold 4,582 Biogen shares in Q4 2024, an estimated $888K.
Mangrove Partners first reported a position in Biogen in Q3 2021 and held it in 2 quarters.
Mangrove Partners's Biogen position peaked at $13M in Q3 2021.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Mangrove Partners's 13F filing for Q4 2024, filed 14 Feb 2025.